United States: Diagnostic Method Claims And Primer Tools Lack Patent-Eligibility

In Roche Molecular Systems, Inc. v Cepheid, (Slip Op. 2017-1690, October 9, 2018), the Federal Circuit held that patent claims directed to primers and methods of detecting pathogenic bacteria using the primers are invalid for failing to claim patent-eligible subject matter. The decision summarizes this panel's current thinking on the patent-eligibility of unmodified polynucleotides and methods to detect "natural phenomena" using "conventional" tools. Also, the panel deferred opining on the patent-eligibility of modified polynucleotides and the use of polynucleotides as therapeutics.

U.S. Patent No. 5,643,723 – Detecting Rifampin Resistance

U.S. Patent No. 5,643,723 ("the '723 Patent"), titled "Detection of a Genetic Locus Encoding Resistance to Rifampin in Microbacterial Cultures and in Clinical Specimens" is owned by Appellant Roche Molecular Systems, Inc. ("Roche"). The '723 Patent claims methods for detecting pathogenic bacterium Mycobacterium tuberculosis ("MTB") and in particular, rifampin-resistant MTB in cultured or clinical samples. MTB infection is a major cause of tuberculosis and rifampin is first-line treatment for treating MTB infection.

Claims 1 and 17 are representative of Roche's asserted claims.

  1. A method for detecting Mycobacterium tuberculosis in a biological sample suspected of containing M. tuberculosis comprising: (a) subjecting DNA from the biological sample to polymerase chain reaction [PCR] using a plurality of primers under reaction conditions sufficient to simplify a portion of a M. tuberculosis rpoB [gene] to produce an amplification product, wherein the plurality of primers comprises at least one primer that hybridizes under hybridizing conditions to the amplified portion of the [gene] at a site comprising at least one position-specific M. tuberculosis signature nucleotide selected, with reference to FIG. 3 (SEQ ID NO: 1), ...:

a G at nucleotide position 2312,

a T at nucleotide position 2313,

an A at nucleotide position 2373,

a G at nucleotide position 2374,

an A at nucleotide position 2378,

a G at nucleotide position 2408,

a T at nucleotide position 2409,

an A at nucleotide position 2426,

a G at nucleotide position 2441,

an A at nucleotide position 2456, and

a T at nucleotide position 2465; and

(b) detecting the presence or absence of an amplification product, wherein the presence of an amplification product is indicative of the presence of M. tuberculosis in the biological sample and wherein the absence of the amplification product is indicative of the absence of M. tuberculosis in the biological sample.

  1. A primer having 14–50 nucleotides that hybridizes under hybridizing conditions to an M. tuberculosis rpoB [gene] at a site comprising at least one position-specific M. tuberculosis signature nucleotide selected, with reference to FIG. 3 (SEQ ID NO: 1), ...:

a G at nucleotide position 2312,

a T at nucleotide position 2313,

an A at nucleotide position 2373,

a G at nucleotide position 2374,

an A at nucleotide position 2378,

a G at nucleotide position 2408,

a T at nucleotide position 2409,

an A at nucleotide position 2426,

a G at nucleotide position 2441,

an A at nucleotide position 2456, and

a T at nucleotide position 2465.

The '723 Patent exploits the discovery that certain mutations are present only in MTB. If a clinician detects one of the eleven "signature nucleotides" from a biological sample, it is a positive result for MTB and in particular, a specific species of MTB – rifampin-resistant MTB. The genetic tests, expressed by the methods and primer tools to perform these tests in the '723 Patent, are faster and more specific than tests available at the time the '723 patent application was filed. Physicians, armed with this knowledge, can avoid prescribing rifampin to patients who will not receive any therapeutic benefit from the drug. Thus, similar to certain companion diagnostics used in precision cancer therapy, genetic tests are employed to determine the most appropriate treatment for the patient at the time of diagnosis, thus avoiding the use of ineffective treatments.

Claims Fail 35 USC § 101

The United States District Court for the Northern District of California found on a motion for summary judgment that the asserted claims of the '723 patent are directed to patent-ineligible subject matter and therefore invalid under 35 U.S.C. § 101. The Federal Circuit affirmed.

The Alice/Mayo Two-Step Test

The Federal Circuit relied on the US Supreme Court's two-step test for distinguishing patents that claim laws of nature, natural phenomena, and abstract ideas from those that claim patent-eligible applications of those concepts. Slip Op. at 8-9, citing Alice Corp. v. CLS Bank Int'l, 134 S. Ct. 2347, 2354 (2014) and Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66, 77–79 (2012). The Alice/Mayo two-step test requires the court to determine whether the claims at issue are directed to a patent-ineligible concept. Slip Op. at 9. At the first step, it is insufficient to merely identify a patent-ineligible concept underlying the claim; the court must also determine whether that patent-ineligible concept is what the claim is "directed to." Slip Op. at 9, citing Rapid Litig. Mgmt. Ltd. v. CellzDirect, Inc., 827 F.3d 1042, 1050 (Fed. Cir. 2016). If the claim is directed to a patent-ineligible concept, then the claim is evaluated to "examine the elements of the claim to determine whether it contains an 'inventive concept' sufficient to 'transform' the claimed abstract idea into a patent-eligible application." Id., citing Alice, 134 S. Ct. at 2357 (quoting Mayo, 566 U.S. at 72–73, 78). The court noted that at this second step, there must be a further inventive concept to take the claim into the realm of patent-eligibility. "For claims that encompass natural phenomena, the method steps are the 'additional features that must be new and useful.'" Id., citing Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371, 1377 (Fed. Cir. 2015) and Genetic Techs. Ltd. v. Merial L.L.C., 818 F.3d 1369, 1376 (Fed. Cir. 2016), cert. denied, 137 S. Ct. 242 (2016).

The Primer Claims

Roche argued that the primer claims were patent-eligible because as artificial, man-made primers they are different from naturally occurring DNA specifically because the claimed primers have both a 3-prime end and a 3-prime hydroxyl group. Naturally occurring, counterpart bacterial MTB DNA contains neither of these. Slip Op. at 10.

The Federal Circuit disagreed with Roche and agreed with the lower court's analysis of the primer claims. The district court had determined that because the primer claims are identical in genetic sequence to those found in nature, the primers are indistinguishable from those held to be directed to nonpatentable subject matter in In re BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig., 774 F.3d 755, 760 (Fed. Cir. 2014) ("BRCA1")). In BRAC1, the Federal Circuit found that similar primer claims were not distinguishable from native DNA. The court stated that:

"It is well established that primers are short, single stranded nucleic acid molecules that bind to their complementary nucleotide sequence. ... As this court found in BRCA1, [p]rimers necessarily contain the identical sequence of the [nucleotide] sequence directly opposite to the [DNA] strand to which they are designed to bind. They are structurally identical to the ends of DNA strands found in nature."

Slip Op. at 10-11, citations omitted.

In reaching this result, the Federal Circuit noted that the Roche inventors did not introduce any mutations that would have made the primers' nucleotide sequences different from those found in nature.

The Federal Circuit also rejected Roche's argument that the linear primers are distinguishable from native MTB DNA that has a circular chromosome, and thus, contains neither a 3-prime end nor a 3-prime hydroxyl group. Slip Op. at 11. The court opined that "the subject matter eligibility inquiry of primer claims hinges on comparing a claimed primer to its corresponding DNA segment on the chromosome—not the whole chromosome." Slip Op. at 12.

Roche's argument that the specificity of the primers distinguishes them from native DNA also was rejected by the court. Roche argued that the claimed primers hybridize to only one of eleven position specific signature nucleotides on the MTB rpoB gene thereby transforming the primers into patent-eligible subject matter. The court did not find the function of the primers as evidence to distinguish the primers from native DNA because in the court's opinion, a primer having an identical nucleotide sequence to naturally occurring DNA without further chemical modification is a natural phenomenon. Slip Op. at 14.

While the court reaffirmed that unmodified nucleotides are patent-ineligible, it expressly withheld judgment on whether modified primers would be patent-eligible. "We do not address the subject matter eligibility of primers that have been altered—e.g., investigator induced mutation(s) such that their nucleotide sequences are not found in nature, or primers which are chemically modified or labeled by investigators such that they cannot be isolated directly from naturally occurring DNA" citing Myriad, 569 U.S. at 596 ("Scientific alteration of the genetic code presents a different inquiry, and we express no opinion about the application of § 101 to such endeavors."). Slip Op. at 13, footnote 5.

The Method Claims

The methods of claim 1 and its dependents were determined by the court to be directed to a patent-ineligible relationship between the eleven naturally occurring position-specific signature nucleotides and the presence of MTB in a sample. In the court's opinion, this "relationship between the signature nucleotides and MTB is a phenomenon that exists in nature apart from any human action, meaning the method claims are directed to a natural phenomenon, which itself is ineligible for patenting." Slip Op. at 15.

Something More Requirement

The court analyzed the method claims in light of the specification which noted in the Summary of the Invention section that "[t]his invention involves a comparative analysis of the rpoB sequences in MTB, other mycobacteria and related . . . bacteria . . . demonstrating the heretofore undiscovered presence of a set of MTB specific position-specific 'signature nucleotides' that permits unequivocal identification of MTB .... Slip Op. at 15, citing the '723 Patent at column 2, lines 60–65 (emphasis added).

The court also focused on the patent language itself which characterized the inventors' discovery as a previously undiscovered natural phenomenon found upon inspection of MTB sequence alignment. The specification noted that the inventors' discovery related to eleven sites at which the nucleotide observed for MTB were different from all or most related organisms. Id. The court concluded that because these signature nucleotides are naturally occurring, the method claims are ineligible for patenting.

The court continued in its analysis by stating that the use of primers in a PCR step in the claims also fails to satisfy the "something more" requirement of the Alice/Mayo test because PCR was "routine" at the time the patent application was filed. The court divorced the use of this technique from its application for MTB detection, noting that "[w]hile it may be true that Roche inventors were the first to use PCR to detect MTB in a biological sample, being the first to discover a previously unknown naturally occurring phenomenon or a law of nature alone is not enough to confer patent eligibility. Many groundbreaking, innovative, and brilliant discoveries have been held patent-ineligible." Slip Op. at 16-17, citing Mayo, 566 U.S. at 73–77 (discovery of natural correlation between level of certain metabolites and drug dosage, resulting in claimed method of optimizing treatment using standard techniques to administer the drug and then check if the metabolite level indicated the need for a dosage change); Genetic Techs., 818 F.3d at 1374 (discovery of natural correlation between non-coding regions of DNA and the presence of an allele in the coding region, resulting in claimed method of detecting alleles using standard PCR to amplify and detect); and Ariosa, 788 F.3d at 1373 (discovery of natural phenomenon that pregnant women's blood contains cffDNA, resulting in claimed methods using standard techniques to amplify and detect cffDNA in maternal blood).

The court also rejected Roche's argument that the use of PCR to detect MTB is no less inventive than the use of an artificial new drug to treat MTB. The court disagreed stating that the primers in the methods do not perform a significantly new function. "Thus, unlike a method of treating a disease with a new drug, Roche's method claims do not involve 'a significantly new function' for the primers. . . This case is distinguishable from CellzDirect, where this court vacated a district court's decision that the method claims at issue were ineligible for patenting. ... This court held that while the claims were based on the discovery of a natural phenomenon (the ability of certain liver cells, or hepatocytes, to survive multiple freeze cycles), they were 'directed to a new and useful laboratory technique for preserving hepatocytes'— namely, freezing and thawing hepatocytes twice even though the prior art taught away from this process. . . This court held that '[t]his type of constructive process, carried out by an artisan to achieve 'a new and useful end,' is precisely the type of claim that is eligible for patenting . . . [The inventors] employed their natural discovery to create a new and improved way of preserving hepatocyte cells for later use." Slip Op. at 18.

The court also distinguished its more recent Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Ltd. decision where claimed methods of treatment are subject matter eligible because they claim a new way of using an existing drug. The court emphasized that Vanda underscores the distinction between method of treatment claims and those in Mayo, i.e., claims "directed to a diagnostic method." Slip Op at 19, footnote 7. In the court's opinion, Roche's method claims, consisting of a standard PCR amplification step and a mental determination step, are not directed to a method of treatment.

The panel further expressly reserved its opinion on the subject matter eligibility of method claims that exploit DNA or RNA (e.g., siRNA or RNAi) for drug-like new applications. Slip Op. at 18, footnote 6.

Patenting Personalized Methods and Tools

The Roche panel made clear that isolated polynucleotides that are identical in primary sequence to a naturally occurring polynucleotide molecule are not patent-eligible. Whether modified polynucleotides are patent-eligible, and if so, what modifications transform patent-eligibility, was left unanswered by the court.

This panel also held that methods of detecting specific genetic mutations in a patient sample are not patent-eligible unless there is "something more" recited in the claim because they are directed to a natural phenomenon. That "something more" must be more than the use of conventional techniques such as PCR, even if the inventors were the first to use the tool for the claimed medical application. Thus, diagnostic or prognostic methods that use conventional techniques to identify natural phenomenon such as genetic alterations, are unlikely to survive a patent-eligibility challenge, absent a recitation of that "something more."

However, even though polynucleotides having identical sequence to a naturally occurring polynucleotide and methods for detecting natural phenomenon that use conventional tools are not patent-eligible, the court reaffirmed that methods of treatment that include diagnostic elements, remain patent-eligible. The court also reaffirmed that use of conventional tools in an unconventional manner to create a new product as explained in CellzDirect, remains patent-eligible.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions